Afinitor-Sandostatin LAR Depot combination extends median PFS in patients with advanced carcinoid tumors
Links shared publicly online about this topic.
- 809total visits
Afinitor-Sandostatin LAR Depot combination extends median PFS in patients with advanced carcinoid tumors
A Novartis Pharmaceuticals Corporation Phase III study of Afinitor® (everolimus) tablets in combination with Sandostatin® LAR Depot (octreotide acetate for injectable suspension) extended median progression-free survival (PFS), or time without tumor growth, in patients with advanced carcinoid tumors compared to taking octreotide LAR alone.
View full resource at news-medical.net
Tags: Kidney Cancer Medication, Pharma, Afinitor, Novartis
Most Recently Shared on October 11, 2010 at 12:05 pm By:
Afinitor-Sandostatin LAR Depot combination extends median PFS in patients with advanced carcinoid tumors: A Novart... http://bit.ly/b0LmUf
Advertisement
